Design and evaluation of endosomolytic biocompatible peptides as carriers for siRNA delivery.

Gene therapy using RNA interference (RNAi) technology has been explored to treat cancers, by regulating the expression of oncogene. However, even though small interfering RNA (siRNA), which triggers RNAi, may have great therapeutic potential, efforts at using them in vivo have been hampered by the difficulty of effective and safe delivery into cells of interest. In this study, to develop a safe and efficient carrier for in vitro and in vivo siRNA delivery, we designed a peptide library. These peptides are improved variants of a known peptide based siRNA carrier C6. All the modifications improved the transfection efficiency of C6 to some degree. After completing prescreening for activity, several promising candidates were used for further evaluation. Selected peptides C6M3 and C6M6 could form stable complexes with siRNA. These complexes could be greatly uptaken by cells and showed a punctate perinuclear distribution. Moreover, peptide/siRNA complexes achieved high transfection efficiency in vitro without inducing substantial cytotoxicity. We have validated the therapeutic potential of this strategy for cancer treatment by targeting Bcl-2 gene in mouse tumor models, and demonstrated that tumor growth was inhibited. In order to address possible immune side effects of these peptide carriers, biocompatibility study in terms of complement activation and cytokine activation assay were carried out, whereas none of the peptides induced such effects. In conclusion, these results support the potential of these peptides as therapeutic siRNA carrier.

Thermodynamic characterization of the interaction between a peptide-drug complex and serum proteins.

The interaction between a peptide-based drug delivery system and two serum proteins, bovine serum albumin (BSA) and immunoglobulin G (IgG), is investigated using fluorescence quenching and calorimetric techniques. An ionic-complementary self/co-assembling peptide, EAR8-II, is employed to encapsulate the hydrophobic anticancer drug pirarubicin (THP) and stabilize it in protein environments. Self/co-assembling properties of the peptide-drug complex (EAR8-II-THP) are shown to be different while interacting with serum proteins compared with the properties of the isolated complex. The results from thermodynamic studies suggest that the drug delivery system has a strong binding affinity (K(SV) 1689 M(-1)), exothermic and enthalpy-driven interaction, with BSA and a relatively weak affinity with IgG (K(SV) 295.2 M(-1)). In the presence of salt ions, the enthalpy and binding affinity remain unchanged, implying other interactions such as hydrogen bonding and Van der Waals interactions are present that are not affected by reduced polarity. This work forms the basis for further studies of EAR8-II-THP complexes in the presence of important proteins and for further evaluation of the complexes' immune response and anticancer activity.

Self/co-assembling peptide, EAR8-II, as a potential carrier for a hydrophobic anticancer drug pirarubicin (THP)--characterization and in-vitro delivery.

A short ionic-complementary peptide, EAR8-II, was employed to encapsulate the hydrophobic anticancer drug pirarubicin (THP). EAR8-II was designed to inherit advantages from two previously introduced peptides, AAP8 and EAK16-II, in their self/co-assembly. This peptide is short, simple, and inexpensive to synthesize, while possessing a low critical assembly concentration (CAC). The choice of alanine (A) residues in the peptide sequence provides moderate hydrophobic interactions, causing a minimal degree of aggregation, compared with other more hydrophobic residues. EAR8-II is an ionic-complementary peptide, similar to EAK16-II, can self/co-assemble with hydrophobic compounds such as THP, and forms a stable fibular nanostructure in aqueous solution. Physiochemical properties and cellular activities of the EAR8-II and THP complexes were evaluated and show dependency on the peptide-to-drug ratio. The complex at the peptide-to-drug mass ratio of 5:1 provides a stable solution, uniform nanostructure, and highly effective anticancer activity against various cancer cell lines. This work forms the basis for detailed studies on EAR8-II and THP formulations in vitro and in vivo, for future development of peptide-based delivery systems for hydrophobic anticancer drugs.

Pharmacokinetics of peptide mediated delivery of anticancer drug ellipticine.

The amino acid pairing peptide EAK16-II (EAK) has shown the ability to stabilize the hydrophobic anticancer agent ellipticine (EPT) in aqueous solution. In this study, we investigate pharmacokinetics of the formulation of EAK-EPT complexes in vivo. The developed formulation can achieve a sufficiently high drug concentration required in vivo animal models. The nanostructure and surface properties of EAK-EPT complexes or nanoparticle were characterized by transmission electron microscopy (TEM) and zeta potential measurements, respectively. 12 healthy male SD rats were divided into EPT group and EAK-EPT group randomly. Rats in EPT group were tail intravenously injected with the EPT (20 mg/kg); rats in EAK-EPT group were injected with EAK-EPT complexes (EPT's concentration is 20 mg/kg). EPT was extracted from rat plasma with dexamethasone sodium phosphate as internal standards (IS). The pharmacokinetic parameters were obtained using high pressure liquid chromatography (HPLC). Significant differences in main pharmacokinetic parameters between EPT and EAK-EPT complexes were observed, demonstrating that the complexation with EAK prolongs the residence time of the drug and enlarges the area under the concentration-time curve (AUC). This means that EAK can serve as a suitable carrier to increase the bioavailability of EPT.

Self-assembling peptide-based nanoparticles enhance anticancer effect of ellipticine in vitro and in vivo.

BACKGROUND AND METHODS: Applications of the anticancer agent, ellipticine, have been limited by its hydrophobicity and toxicity. An efficient delivery system is required to exploit the enormous potential of this compound. Recently, EAK16-II, an ionic-complementary, self-assembling peptide, has been found to stabilize ellipticine in aqueous solution. Here, the anticancer activity of ellipticine encapsulated in EAK16-II (EAK-EPT) was evaluated in vitro and in vivo. RESULTS: Our cellular uptake, toxicity, and apoptosis results in an A549 human lung carcinoma cell line indicate that EAK-EPT complexes are significantly more effective than treatment with EAK16-II or ellipticine alone. This is due to the ability of EAK16-II to stabilize ellipticine in a protonated state in well formed nanostructures approximately 200 nm in size. In vivo observations in an A549 nude mouse tumor model show higher antitumor activity and lower cytotoxicity of EAK-EPT complexes than in the control group treated with ellipticine alone. Tumor growth in animals was significantly inhibited after treatment with EAK-EPT complexes, and without any apparent side effects. CONCLUSION: The anticancer activity observed in this study coupled with minimal side effects encourages further development of peptide-mediated delivery of anticancer drugs, ellipticine in the present case, for clinical application.

Diethylene glycol functionalized self-assembling peptide nanofibers and their hydrophobic drug delivery potential.

Self-assembling peptide nanofibers have emerged as important nanobiomaterials, with such applications as delivery of therapeutic agents and vaccines, nanofabrication and biomineralization, tissue engineering and regenerative medicine. Recently a new class of self-assembling peptides has been introduced, which takes into consideration amino acid pairing (AAP) strategies in the peptide sequence design. Even though these peptides have shown promising potential in the design of novel functional biomaterials, they have a propensity to initiate uncontrollable aggregation and be degraded by proteolytic enzymes. These present the most significant challenge in advancing self-assembling peptides for in vitro and in vivo applications. Functionalizing biomaterials with polyethylene glycol (PEG) has been shown to surmount such problems. Here the results of conjugating diethylene glycol (DEG), a short segment of PEG, to one of the AAP peptides, AAP8, with eight amino acids in sequence, are reported. The results indicate that incorporation of DEG into the peptide sequence modulates fiber self-assembly through creating more aligned and uniform nanostructures. This is associated with increasing solubility, stability, and secondary structure ß-sheet content of the peptide. The DEG conjugate of AAP8 also shows reduced cellular cytotoxicity. Functionalization of AAP8 improves the capability of the peptide to stabilize and deliver a hydrophobic anticancer compound, ellipticine, in aqueous solution, consequently inducing greater cytotoxicity to lung carcinoma cells over a relatively long time, compared with non-functionalized AAP8. The presented functionalized peptide and its drug delivery application indicate a potentially useful design strategy for novel self-assembling peptide biomaterials for biotechnology and nanomedicine.

Self-assembling peptides: potential role in tumor targeting.

This review focuses on the application of two classes of peptides, i.e., self-assembling peptides (SAPs) and cell-targeting peptides (CTPs), in the development of nanocarrier delivery systems. Self-assembling peptides are emerging in a wide range of biomedical and bioengineering applications and fall into several classes, including peptide amphiphilies, bolaamphiphile peptides, cyclic peptides, and ionic complementary peptides, which can be found naturally or synthesized. The advantage of synthesizing peptides is that their self-assembling properties can be exploited to form desirable structures for various applications. Another, unique property of self-assembling peptides, is stimuli-responsibility in different environments including various pHs, temperatures, ionic strengths, etc. These characteristics make peptides applicable in a wide range of biomaterials in drug discovery. This study reviews the design principles of well-known self-assembling peptides, as well as their physical/chemical properties. In addition, it discusses the therapeutic cancer-targeting peptides and current combinatorial peptide library methods used to identify targeting peptides. Cancer-targeting peptides can target either tumor cell surfaces or tumor vasculature. The RGD peptide is one of the first tumor-targeting peptides that can bind to self-assembling peptides or any other nanocarrier to improve the therapeutic efficiency of targeting drug delivery systems.